Literature DB >> 17664235

Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?

M L Ishimori1, B D Pressman, D J Wallace, M H Weisman.   

Abstract

A variety of neuropsychiatric findings may complicate systemic lupus erythematosus (SLE) and pose diagnostic and therapeutic dilemmas. We describe the clinical and radiographic features of posterior reversible encephalopathy syndrome (PRES) and distinguish PRES from other conditions seen in SLE. Patient charts and magnetic resonance imaging (MRI) findings of four patients with SLE on immunosuppressive therapy with acute or subacute neurologic changes initially suggesting cerebritis or stroke were reviewed. The English language literature was reviewed using the Medline databases from 1996-2006 for other reports of PRES with SLE. Literature review yielded 26 other SLE cases reported with PRES. SLE patients with PRES were more commonly on immunosuppressive drugs, had episodes of relative hypertension, and had renal involvement. Characteristic findings are seen on MRI, which differentiate PRES from other CNS complications of SLE. Clinical and radiographic resolution of abnormalities within 1-4 weeks is typically seen. PRES has been increasingly recognized. Reversible changes are found on brain MRI accompanied by sometimes dramatic signs and symptoms. The therapeutic implications for separating PRES from stroke or cerebritis are important. We propose that PRES should be considered in the differential diagnosis in SLE patients with new-onset neurologic signs and symptoms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664235     DOI: 10.1177/0961203307078682

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  13 in total

1.  Differential serum cytokine profile in patients with systemic lupus erythematosus and posterior reversible encephalopathy syndrome.

Authors:  J Merayo-Chalico; A Barrera-Vargas; G Juárez-Vega; J Alcocer-Varela; A Arauz; D Gómez-Martín
Journal:  Clin Exp Immunol       Date:  2018-01-16       Impact factor: 4.330

2.  MR imaging findings suggestive of posterior reversible encephalopathy syndrome in adolescents with systemic lupus erythematosus.

Authors:  Eyal Muscal; Elfrides Traipe; Marietta M de Guzman; Barry L Myones; Robin L Brey; Jill V Hunter
Journal:  Pediatr Radiol       Date:  2010-01-30

3.  Age and gender may affect posterior reversible encephalopathy syndrome in renal disease.

Authors:  Akio Yamada; Norishi Ueda
Journal:  Pediatr Nephrol       Date:  2011-08-07       Impact factor: 3.714

4.  A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide.

Authors:  M Jabrane; Z Ait Lahcen; W Fadili; I Laouad
Journal:  Rheumatol Int       Date:  2014-11-12       Impact factor: 2.631

Review 5.  The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients.

Authors:  Tatjana Zekić; Mirjana Stanić Benić; Ronald Antulov; Igor Antončić; Srđan Novak
Journal:  Rheumatol Int       Date:  2017-10-17       Impact factor: 2.631

6.  Posterior reversible encephalopathy syndrome as the first clinical manifestation of lupus nephritis.

Authors:  Frederico Carvalho de Medeiros; Bárbara Márcia Rocha Sousa; Dandara Noária Cruz Santos; Gisele Novais Matias Sion; Cibele Fontes Alves
Journal:  Acta Neurol Belg       Date:  2021-02-16       Impact factor: 2.396

7.  Chorea as the first and only manifestation of systemic lupus erythematosus.

Authors:  Abdul Razzakh Poil; Fahmi Yousef Khan; Abdo Lutf; Mohammed Hammoudeh
Journal:  Case Rep Rheumatol       Date:  2012-09-16

8.  Gemcitabine monotherapy associated with posterior reversible encephalopathy syndrome.

Authors:  Luiz Carlos Porcello Marrone; Bianca Fontana Marrone; Julia de la Puerta Raya; Giovani Gadonski; Jaderson Costa da Costa
Journal:  Case Rep Oncol       Date:  2011-02-16

9.  Posterior reversible encephalopathy syndrome could be an underestimated variant of "reversible neurological deficits" in Systemic Lupus Erythematosus.

Authors:  Bin Liu; Xuan Zhang; Feng-Chun Zhang; Yuan Yao; Ri-Zhi Zhou; Miao-Miao Xin; Li-Qin Wang
Journal:  BMC Neurol       Date:  2012-12-05       Impact factor: 2.474

10.  Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study.

Authors:  Usanee Damrongpipatkul; Kanokporn Oranratanachai; Nuntana Kasitanon; Salita Wuttiplakorn; Worawit Louthrenoo
Journal:  Clin Rheumatol       Date:  2017-11-04       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.